Imetelstat Improves Rate of Durable Transfusion Independence in Patients With Lower-Risk MDS
Treatment with imetelstat, a competitive inhibitor of telomerase enzymatic activity, was associated with a clinically meaningful rate of transfusion independence in heavily transfused patients with lower-risk
Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome
Abstract
The metabolic reprogramming in acute myeloid leukemia patients depends on their genotype and is a prognostic marker
Key Points
Different metabolic pathways are involved in intracellular metabolic reprogramming depending on the genetic characteristics of AML cells.
Leukemic progenitors activate different programs of the metabolism, depending on their levels of differentiation blockade.
(Article continues at link.)
Clinical development of our investigational therapy, pegcetacoplan
Dear members of the PNH community,
Naval G. Daver, MD, on the Past Year in Acute Myeloid Leukemia Research
Pegcetacoplan Bests Eculizumab for PNH Patients
Results from the phase III PEGASUS trial suggest that the targeted C3 inhibitor pegcetacoplan improved hemoglobin levels better than eculizumab in patients with